Skip to main content
Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc. — Investor Relations & Filings

Ticker · NRIX US Professional, scientific and technical activities
Filings indexed 484 across all filing types
Latest filing 2026-04-08 Interim / Quarterly Rep…
Country US United States of America
Listing US NRIX

About Nurix Therapeutics, Inc.

https://www.nurixtx.com/

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of medicines based on targeted protein degradation. The company's proprietary DEL-AI drug discovery engine is used to create therapies that harness the body's natural cellular machinery to eliminate disease-causing proteins. Its pipeline features multiple modalities, including small molecule degraders and Degrader Antibody Conjugates (DACs), which combine the specificity of an antibody with the catalytic potency of a degrader. These investigational therapies are being advanced for the treatment of various cancers and autoimmune diseases.

Recent filings

Filing Released Lang Actions
10-Q - Nurix Therapeutics, Inc. (0001549595) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-08 English
8-K - Nurix Therapeutics, Inc. (0001549595) (Filer)
Regulatory Filings
2026-04-08 English
SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)
Major Shareholding Notification
2026-03-27 English
ARS - Nurix Therapeutics, Inc. (0001549595) (Filer)
Annual Report
2026-03-27 English
DEFA14A - Nurix Therapeutics, Inc. (0001549595) (Filer)
Regulatory Filings
2026-03-27 English
DEF 14A - Nurix Therapeutics, Inc. (0001549595) (Filer)
Proxy Solicitation & Information Statement
2026-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.